Spruce Biosciences Prices $60M Public Offering at 28% Discount, Potentially Doubling Shares Outstanding

summarizeSummary

Spruce Biosciences finalized a highly dilutive $60 million public offering at a deep 28% discount to the prior day's closing price, providing critical capital to extend its operational runway but significantly impacting existing shareholders.

check_boxKey Events

• Offering Finalized and Priced

  Spruce Biosciences finalized the terms of its underwritten public offering, selling 1,150,000 shares of common stock and pre-funded warrants to purchase 50,000 shares.

• Deep Discount to Market Price

  The offering was priced at $50.00 per share (or $49.99 per pre-funded warrant), representing a substantial 28.46% discount from the common stock's closing price of $69.89 on April 20, 2026.

• Substantial Capital Raise

  The company expects to receive approximately $56.4 million in net proceeds, which could increase to $64.9 million if the underwriters fully exercise their option to purchase an additional 180,000 shares.

• Highly Dilutive Transaction

  The offering is highly dilutive, with the potential to increase the number of outstanding shares by over 100% if all shares and warrants are issued and the option is exercised.

auto_awesomeAnalysis

Spruce Biosciences has finalized the terms of its underwritten public offering, pricing 1,150,000 shares of common stock and pre-funded warrants for 50,000 shares at $50.00 per share (or $49.99 per warrant). This pricing represents a significant 28.46% discount to the common stock's closing price of $69.89 on April 20, 2026. The offering is expected to generate approximately $56.4 million in net proceeds, potentially increasing to $64.9 million if the underwriters fully exercise their option to purchase an additional 180,000 shares. This capital raise is critical for the company, which previously disclosed substantial doubt about its ability to continue as a going concern, and is projected to fund operations through the second half of 2027. However, the offering is highly dilutive, with the potential to increase the number of outstanding shares by over 100%, significantly impacting existing shareholder value.